ライフサイエンスコーパス: surface glycoprotein

1 e third hypervariable (V3) loop of the HIV-1 surface glycoprotein.

2 contained mutations in the hr1 region of the surface glycoprotein.

3 DD for nsp6, nucleocapsid (N), and spike (S) surface glycoprotein.

4 infectivity by binding to the E2 (envelope) surface glycoprotein.

5 tive metacyclic forms expressing the variant surface glycoprotein.

6 receptor-binding site on the haemagglutinin surface glycoprotein.

7 osomes, of pre-existing cell surface variant surface glycoprotein.

8 quence changes in the V3 region of the gp120 surface glycoprotein.

9 hatidylinositol-anchored (GPI-anchored) cell surface glycoprotein.

10 bound glycoprotein by ELISA recognized cell-surface glycoprotein.

11 cognizes an epitope in the glycan cap of the surface glycoprotein.

12 ies that target the hemagglutinin (HA) viral surface glycoprotein.

13 Clr-a as a disulfide-linked homodimeric cell surface glycoprotein.

14 n, clustering, endocytosis, and signaling of surface glycoproteins.

15 ed alpha2,3 or alpha2,6 sialic acids on cell surface glycoproteins.

16 Here we report that CTB binds cell surface glycoproteins.

17 binding to terminally sialylated glycans on surface glycoproteins.

18 on CTLs may be linked to reduced motility of surface glycoproteins.

19 g, corroborating an increase in high mannose surface glycoproteins.

20 rther arises from differential expression of surface glycoproteins.

21 ation of 2172 N-glycosylation sites and 1047 surface glycoproteins.

22 rated into O-GlcNAcylated proteins over cell-surface glycoproteins.

23 e trafficking, activity, and localization of surface glycoproteins.

24 ee new anti-HIV aptamers targeting the viral surface glycoprotein 120 (gp120) were selected, synthesi

25 docytosis involving the parasite's invariant surface glycoprotein 75 (ISG75), followed by transport i

26 ntitrypanosomal drug, suramin, via invariant surface glycoprotein 75, and in the uptake of trypanosom

27 ce proteomes, being dominated by the variant surface glycoprotein (African) or mucins (American) resp

28 orption of an antibody specific for a virion surface glycoprotein allowed differentiation of MCMV fro

29 quence) gene family encodes eight large cell-surface glycoproteins (Als1-Als7 and Als9) that have adh

30 Major surface glycoprotein also down regulated Dectin-1 recept

31 orchestrated via the concerted action of two surface glycoproteins: an attachment protein called hema

32 t stage, enabling rapid recycling of variant surface glycoprotein and antibody clearance from the sur

33 The RSV F protein is a highly conserved surface glycoprotein and is the main target of neutraliz

34 rophobic helical structures, from the HCV E2 surface glycoprotein and the CD81 protein, a major host

35 Many viral surface glycoproteins and cell surface receptors are hom

36 any cellular processes by oligomerizing cell surface glycoproteins and glycolipids into higher-order

37 cine include the variability of the envelope surface glycoproteins and its high-density glycan shield

38 ptamer conjugates against two different cell surface glycoproteins and show that these reagents are a

39 Thus, RSV surface glycoproteins are continuously evolving, and con

40 izing antibodies targeting influenza A virus surface glycoproteins are critical components of influen

41 mechanisms of diseases and the discovery of surface glycoproteins as biomarkers and drug targets.

42 ical communities and aid in the discovery of surface glycoproteins as disease biomarkers and drug tar

43 irulence and express the VEEV and EEEV E2/E1 surface glycoproteins as vaccine antigens.

44 nd #10 antibodies can be used to detect cell surface glycoproteins bearing O-GlcNAc.

45 to date have incorporated the RSV fusion (F) surface glycoprotein, because the sequence of F is highl

46 These polymorphic cell-surface glycoproteins bind peptide antigens, forming lig

47 ood cells and inflammatory cells (macrophage surface glycoproteins binding to galectin-3) and an incr

48 GPIHBP1, an endothelial cell-surface glycoprotein, binds LPL and is required for the

49 involving the switching of expressed variant surface glycoproteins by a stochastic and parasite-intri

50 Galectin-3 (Gal-3) can cross-link surface glycoproteins by binding galactose residues that

51 We reported that removing a specific set of surface glycoproteins by ex vivo treatment with O-sialog

52 gambiense surface glycoproteins can be inhibited by circulating an

53 We demonstrate that S1 is a cell surface glycoprotein capable of binding to host SLAMF6.

54 The cell-surface glycoprotein CD44 is expressed in chronic lympho

55 The cell surface glycoprotein CD44 plays an important role in the

56 n MSC expression of the multifunctional cell surface glycoprotein CD44, a putative stem cell marker.

57 Previous studies have implicated the surface glycoproteins CD44 and carcinoembryonic antigen

58 ding bovine submaxillary mucin and leukocyte surface glycoproteins CD45 and P-selectin glycoprotein l

59 Here, we investigated whether the cell surface glycoprotein CD47 was required for normal format

60 gulatory molecules, including the inhibitory surface glycoprotein CD5, are up-regulated in proportion

61 tly, IL-6 was found to also bind to the cell surface glycoprotein CD5, which would then engage gp130

62 The T cell-surface glycoprotein CD6 is a modulator of cellular resp

63 We report that the surface glycoprotein CD62L can be characterized as a nov

64 ound that CD26, in combination with the cell surface glycoprotein CD90, identifies a distinct subpopu

65 We have identified the cell surface glycoprotein CDCP1 as a key regulator of EGF/EGF

66 hell in a rationally arranged fashion with a surface glycoprotein coated on to the surface and non-st

67 sponses target mainly the hemagglutinin (HA) surface glycoprotein, composed of the head and the stalk

68 the viral polymerases and the hemagglutinin surface glycoprotein conferred respiratory droplet trans

69 The surface glycoprotein contains a free cysteine at residue

70 ly active isoforms: a membrane-spanning cell surface glycoprotein (csCSF-1), a secreted proteoglycan

71 Regions within the HCV surface glycoproteins E1 and E2 are essential for virus

72 the lack of structural information about its surface glycoproteins E1 and E2, the two constituents of

73 HCV is an enveloped virus with two surface glycoproteins (E1 and E2).

74 Antibodies targeting the Ebola virus surface glycoprotein (EBOV GP) are implicated in protect

75 reduce binding affinity with the lentiviral surface glycoprotein, Env.

76 the procyclic form caused underglycosylated surface glycoprotein EP-procyclin.

77 ei results in derepression of silent variant surface glycoprotein ESs, as had previously been shown f

78 position of the gC-null virus, including the surface glycoproteins essential for entry, was equivalen

79 cell adhesion molecule (EpCAM) (CD326) is a surface glycoprotein expressed by invasive carcinomas an

80 cell adhesion molecule-2 (CEACAM2) is a cell-surface glycoprotein expressed on blood, epithelial, and

81 BAI1 (termed Vstat120) requires CD36, a cell surface glycoprotein expressed on microvascular endothel

82 uences the choice of a monocistronic variant surface glycoprotein expression site.

83 crothrombocytopenic and had reduced platelet surface glycoprotein expression, including GPVI, alphaII

84 rculating antibodies against the Ebola virus surface glycoprotein for more than a decade after infect

85 s in GNE activity can alter affinity of cell-surface glycoproteins for the galectin lattice.

86 The variable surface glycoprotein from African Trypanosomes was chose

87 erate viral pseudoparticles that contain the surface glycoprotein from the pathogenic virus incorpora

88 -based proteomics, we globally characterized surface glycoproteins from eight popular types of human

89 clonal antibodies using a set of recombinant surface glycoproteins from Reston, Tai Forest, Bundibugy

90 Understanding how the Ebola virus surface glycoprotein functions to facilitate entry in ce

91 pseudotyped with vesicular stomatitis virus surface glycoprotein G (VSV-G).

92 we describe the crystal structure of the RSV surface glycoprotein G in complex with a broadly neutral

93 The virus surface glycoprotein (G) has been shown to direct BDV ce

94 the Rhabdoviridae family, contains a single surface glycoprotein (G) that is responsible for attachm

95 endocytosis, a process mediated by the virus surface glycoprotein (G), but the cellular factors and p

96 The cell surface glycoprotein gamma-glutamyl transpeptidase (GGT)

97 We found homologs to herpesvirus surface glycoprotein gB in cytoplasmic viruses.

98 ted a monoclonal antibody raised against CMV surface glycoprotein (gB) with gold nanoparticles (GNP)

99 VSV) vector backbone that lacks the native G surface glycoprotein gene (VSVDeltaG).

100 A was analogous to 10(3) copies of the major surface glycoprotein gene per 25 mul of BALF, correspond

101 ar stomatitis virus (serotype Indiana) whose surface glycoprotein gene was replaced by the Zaire Ebol

102 Here, an enzyme is exploited to tag surface glycoproteins, generating a chemical handle for

103 n leads to deregulation of telomeric variant surface glycoprotein genes, linking the function of this

104 Even though the two viral surface glycoproteins Gn and Gc are involved in host cel

105 rus assembly and budding are governed by the surface glycoproteins Gn and Gc.

106 Synthesis of the surface glycoprotein GP of Ebola virus (EBOV) is depende

107 the mutations identified in the Ebola virus surface glycoprotein (GP(12)) observed in all 48 genomes

108 nd that neutralising antibodies to the viral surface glycoprotein (GP) are potential correlates of pr

109 Synthesis of Ebola virus (EBOV) surface glycoprotein (GP) is dependent on transcriptiona

110 The surface glycoprotein (GP) is responsible for Ebola virus

111 monoclonal antibodies (MAbs) that target the surface glycoprotein (GP) of Ebola virus (EBOV) are effe

112 oclonal antibody (mAb) cocktails against the surface glycoprotein (GP) present a potential therapeuti

113 In addition to its surface glycoprotein (GP), Ebola virus directs the produ

114 a proinflammatory signature triggered by the surface glycoprotein (GP), which can be inhibited by blo

115 s the transmembrane-anchored, trimeric viral surface glycoprotein (GP).

116 The Ebola virus (EBOV) surface glycoprotein (GP1,2) mediates host cell attachme

117 The EBOV surface glycoprotein (GP1,2) plays important roles in vi

118 Ebolaviruses have a surface glycoprotein (GP1,2) that is required for virus

119 two amino acid changes, one within the virus surface glycoprotein (GP1: F260L) and the other within t

120 cleaved by cellular proteases to the mature surface glycoprotein gp120 and the transmembrane glycopr

121 The HIV-1 surface glycoprotein gp120 has been reported to bind and

122 hly variable and immunogenic region of HIV-1 surface glycoprotein gp120, and structural information a

123 1 by interacting with their respective viral surfaces (glycoprotein gp120 of HIV and the fivefold axi

124 A hollow (Phe43 cavity) between HIV-1 surface glycoprotein (gp120) and cluster of differentiat

125 of a transmembrane glycoprotein (gp41) and a surface glycoprotein (gp120).

126 imeric complex of heterodimers composed of a surface glycoprotein, gp120, and a transmembrane compone

127 Regions within the virus surface glycoprotein (GPC) and nucleoprotein (NP) are th

128 antibody responses primarily target the LASV surface glycoprotein (GPC), and GPC-B competition group

129 Influenza viruses possess two surface glycoproteins, haemagglutinin and neuraminidase

130 Abnormal expression of TACSTD2 cell-surface glycoprotein has been reported in most epithelia

131 rized human antibodies specific to the viral surface glycoproteins (HBsAg) from memory B cells of HBV

132 s and detailed molecular mechanisms of viral surface glycoprotein hemagglutinin (HA) binding with a b

133 Cleavage of the viral surface glycoprotein hemagglutinin (HA) by host protease

134 o induce neutralizing antibodies against the surface glycoprotein hemagglutinin (HA) is the primary m

135 eviously shown that vaccination of the major surface glycoprotein hemagglutinin (HA) of influenza vir

136 ified amino acids in antigenic site B of the surface glycoprotein hemagglutinin (HA) that explain the

137 nic properties are largely determined by the surface glycoprotein hemagglutinin (HA), and amino acid

138 n occurs through the binding formed by viral surface glycoprotein hemagglutinin and certain types of

139 differences, which generally agreed with the surface glycoprotein hemagglutinin esterase phylogeny, w

140 s with the cell surface is controlled by the surface glycoproteins hemagglutinin (HA) and neuraminida

141 l-mediated immunity, often against the viral surface glycoproteins hemagglutinin (HA) and neuraminida

142 us and have been licensed for human use, the surface glycoproteins hemagglutinin (HA) and neuraminida

143 e transmissibility is the interaction of the surface glycoproteins hemagglutinin (HA) and neuraminida

144 luenza virus induces antibodies to the viral surface glycoproteins hemagglutinin and neuraminidase, a

145 Alterations in the viral surface glycoprotein, hemagglutinin (HA), typically are

146 The surface glycoproteins, hemagglutinin, and neuraminidase

147 This study focuses on the major surface glycoprotein hemagglutinins from both of these n

148 ody responses against the hemagglutinin (HA) surface glycoprotein; however, the diversity of HAs acro

149 infectious virus in the absence of their own surface glycoprotein if a suitable glycoprotein from a f

150 Mucin-4 (Muc4) is a large cell surface glycoprotein implicated in the protection and lu

151 le NST gene results in measurable defects in surface glycoproteins in different life cycle stages of

152 this question, we profiled the abundance of surface glycoproteins in WT and CRISPR-mediated GNPTAB(-

153 The current research indicates that multiple surface glycoproteins including their abundances need to

154 Galectin-3 binding to cell surface glycoproteins, including branched N-glycans gene

155 ect expression and functions of CD44, a cell-surface glycoprotein influencing immunologic, inflammato

156 ring with the endocytic transport of variant surface glycoprotein is a highly desirable strategy for

157 an EBOV vaccine candidate in which the viral surface glycoprotein is biomanufactured as a fusion to a

158 comprehensive and site-specific analysis of surface glycoproteins is much more challenging and drama

159 A bloodstream stage-specific invariant surface glycoprotein (ISG75) family mediates suramin upt

160 The propinquity of CD22 and cell-surface glycoprotein ligands has led to the conclusion t

161 panosome surface proteins, including variant surface glycoprotein, likely facilitating complex biogen

162 ies maintained a similar organization of the surface glycoproteins, matrix protein (M), M2-1, and the

163 nsional density maps show how the hantavirus surface glycoproteins, membrane, and ribonucleoprotein a

164 atitis virus (VSV) expressing the HBV middle surface glycoprotein (MHBs) elicits functional immune re

165 essing the hepatitis B virus middle envelope surface glycoprotein (MS) that induces strong MS-specifi

166 ic responses to Pneumocystis jirovecii major surface glycoprotein (Msg) antigen in African cohorts, o

167 Pneumocystis major surface glycoprotein (Msg) is a 120-kD surface protein c

168 acilitating switching of the expressed major surface glycoprotein (Msg) variant.

169 The major surface glycoprotein (Msg), which is the most abundant p

170 t fragments that span the P. jirovecii major surface glycoprotein: MsgA (amino terminus), MsgB (middl

171 The cell-surface glycoprotein MUC1 is a particularly appealing ta

172 Cell surface glycoprotein MUC18 (alias CD146 or melanoma cell

173 es only one of the unique metacyclic variant surface glycoprotein (mVSG) coat protein transcripts ide

174 cosylation of HA and the other two major IAV surface glycoproteins, neuraminidase (NA) and M2 ion cha

175 sion of the hemagglutinin-neuraminidase (HN) surface glycoprotein of human parainfluenza virus type 3

176 richia coli was able to solubilize the major surface glycoprotein of Pneumocystis, thus potentially f

177 stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is

178 ee adenovirus 3 (ChAd3) vaccine encoding the surface glycoprotein of Zaire ebolavirus (ZEBOV) to 60 h

179 s virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus.

180 These results indicate that the surface glycoproteins of batMuV are serologically and fu

181 al basis of the interaction of the two major surface glycoproteins of influenza A virus with their co

182 (NA) is a sialidase that is one of the major surface glycoproteins of influenza A viruses and the tar

183 Haemagglutinin and neuraminidase surface glycoproteins of the bat influenza H17N10 virus

184 d nine amino acid changes in the Ebola virus surface glycoprotein, of which one resulted in reduced b

185 on of newly synthesized GPI-anchored variant surface glycoprotein on the cell surface.

186 Mass spectrometry of total surface glycoproteins on platelets isolated from wild-ty

187 rophoblast cell-surface marker (Trop-2) is a surface glycoprotein originally identified in human plac

188 Folate (FA) receptor is a cell surface glycoprotein overexpressed on many cancer cells.

189 on average 953 N-glycosylation sites on 393 surface glycoproteins per experiment were identified in

190 Surface glycoproteins play critically important roles in

191 timulated by direct Gal-1 engagement to cell surface glycoproteins, principally CD45, on activated Th

192 ent methods are required for the analysis of surface glycoproteins prior to MS measurement.

193 The hemagglutinin (HA) surface glycoprotein promotes influenza virus entry and

194 tain the cell density of its crucial variant surface glycoprotein protective coat.

195 CPD of the ORFs for the G and F surface glycoproteins provided the greatest restrictive

196 L) cells express high levels of CD44, a cell-surface glycoprotein receptor for hyaluronic acid.

197 Here, we report the structure of the JUNV surface glycoprotein receptor-binding subunit (GP1) boun

198 In this study, we explore the role of surface glycoprotein receptors and signaling proteins in

199 also expressed on several different platelet surface glycoprotein receptors.

200 Cell surface glycoproteins recognized by CTD110.6 antibody in

201 The epitopes of the Lassa virus (LASV) surface glycoproteins recognized by naturally infected h

202 Surface glycoproteins regulate nearly every extracellula

203 Influenza hemagglutinin is a surface glycoprotein related to virus invasion and host

204 Tissue factor (TF) is a cell-surface glycoprotein responsible for initiating the coag

205 nv) and influenza hemagglutinin (HA) are the surface glycoproteins responsible for viral entry into h

206 ins and the glycan ligands presented on cell surface glycoproteins results in high-avidity binding th

207 of entry of HIV-1 pseudotyped with SARS-CoV surface glycoprotein S (SARS-S) but not that of HIV-1 ps

208 ainst axonal guidance cues, such as the cell surface glycoproteins Semaphorin 1a (Sema 1a) and Fascic

209 class I-related chain A (MICA) antigens are surface glycoproteins strongly implicated in innate immu

210 rom the FeLV-A prototype, FeLV-A/61E, in the surface glycoprotein (SU) and long terminal repeat (LTR)

211 tions and, therefore, reduce the motility of surface glycoproteins, such as the T-cell receptor.

212 ce proteins, especially a unique and complex surface glycoprotein superfamily, as well as proteases a

213 c sugar composition of the parasites variant surface glycoprotein synthesized in cells incubated in 5

214 glycosyl phosphatidylinositol-anchored cell surface glycoprotein T-cadherin (encoded by Cdh13) prote

215 nditions are mild, which are well-suited for surface glycoprotein tagging.

216 Alpha-dystroglycan (alpha-DG) is a cell-surface glycoprotein that acts as a receptor for both ex

217 Glypican-3 is a cell surface glycoprotein that associates with Wnt in liver c

218 B, type I (SR-BI), is a homooligomeric cell surface glycoprotein that controls HDL structure and met

219 ound that antibodies to glycoprotein (g)B, a surface glycoprotein that has been developed as a HCMV v

220 CD200 (OX-2) is a cell surface glycoprotein that imparts immune privileges by s

221 (TF) (CD142) is a 47 kDa transmembrane cell surface glycoprotein that triggers the extrinsic coagula

222 on protein PrP(C) is a Cu(2)(+)-binding cell surface glycoprotein that, when misfolded, is responsibl

223 driven by antigenic changes (drift) in viral surface glycoproteins that allow evasion from preexistin

224 ranscripts of trypomastigote-associated cell-surface glycoproteins that are preferentially expressed

225 , FRbeta and FRgamma) are cysteine-rich cell-surface glycoproteins that bind folate with high affinit

226 eptors (KIR) are structurally unrelated cell surface glycoproteins that evolved independently to func

227 rogrammed death ligand 1) and PD-L2 are cell-surface glycoproteins that interact with programmed deat

228 MHC class II (MHCII) molecules are cell surface glycoproteins that play an important role to dev

229 patibility (MHC) class II molecules are cell surface glycoproteins that present extracellular antigen

230 y specific carbohydrate moieties on specific surface glycoproteins that serve as receptors for typhoi

231 Influenza viruses express two surface glycoproteins, the hemagglutinin (HA) and the ne

232 Considering the importance of surface glycoproteins, this method is expected to have e

233 nfluenza viruses bind by their hemagglutinin surface glycoprotein to sialic acid (N-acetylneuraminic

234 Enveloped viruses utilize surface glycoproteins to bind and fuse with a target cel

235 Host cell components prime these viral surface glycoproteins to catalyze membrane fusion at spe

236 Enveloped viruses use their surface glycoproteins to catalyze membrane fusion, an es

237 bind to branched N-glycans attached to cell surface glycoproteins to control the distribution, clust

238 Enveloped viruses utilize transmembrane surface glycoproteins to gain entry into target cells.

239 The cell surface glycoprotein Trask/CDCP1 is phosphorylated durin

240 orses immunized with nanoparticles harboring surface glycoprotein trimers of EBOV-Zaire/Makona produc

241 ody that binds carbonic anhydrase IX, a cell surface glycoprotein ubiquitously expressed in clear cel

242 Its surface glycoproteins undergo proteolytic cleavage and r

243 components are proteases, which cleave viral surface glycoproteins, unleashing them to refold in ways

244 and has a Thr280Ileu mutation in the capsid surface glycoprotein VP7.

245 escribe a protein complex sustaining variant surface glycoprotein (VSG) allelic exclusion and antigen

246 odically switching the dense coat of variant surface glycoprotein (VSG) at the cell surface.

247 ends upon switches in its protective Variant Surface Glycoprotein (VSG) coat by antigenic variation.

248 se by repeatedly replacing its dense variant surface glycoprotein (VSG) coat from its large genomic V

249 ses only 1 of thousands of different variant surface glycoprotein (VSG) coat genes.

250 ckness, constantly changes its dense variant surface glycoprotein (VSG) coat to avoid elimination by

251 odies by periodically changing their variant surface glycoprotein (VSG) coat.

252 riation, a periodic switching of its variant surface glycoprotein (VSG) coat.

253 mune system through replacement of a variant surface glycoprotein (VSG) coat.

254 is protected by an essential coat of Variant Surface Glycoprotein (VSG) comprising approximately 10%

255 of the RNA polymerase I transcribed variant surface glycoprotein (VSG) expression sites (ESs) of Try

256 tion is altered at telomere-proximal variant surface glycoprotein (VSG) expression sites (ESs), sugge

257 lation of telomere-proximal silenced variant surface glycoprotein (VSG) expression sites and procycli

258 in the human bloodstream, expresses variant surface glycoprotein (VSG) from 1 of 15 bloodstream expr

259 -I) to transcribe just one telomeric variant surface glycoprotein (VSG) gene at a time, producing sup

260 , Trypanosoma brucei transcribes its variant surface glycoprotein (VSG) gene expression sites (ESs) i

261 RNA polymerase I (Pol I)-transcribed variant surface glycoprotein (VSG) gene expression sites (ESs),

262 rough DNA-repair processes involving Variant Surface Glycoprotein (VSG) gene rearrangements at subtel

263 lly implicated both ZC3H proteins in variant surface glycoprotein (VSG) gene silencing.

264 pression and reversible silencing of variant surface glycoprotein (VSG) genes found adjacent to telom

265 rypanosoma brucei is used for moving variant surface glycoprotein (VSG) genes into expression sites d

266 Allelic exclusion of variant surface glycoprotein (VSG) genes is essential for Africa

267 expresses one of approximately 1500 variant surface glycoprotein (VSG) genes while multiplying in th

268 can trypanosomes possess hundreds of variant surface glycoprotein (VSG) genes, but only one is expres

269 ally expresses one of more than 1000 Variant Surface Glycoprotein (VSG) genes.

270 Th1 cell responses to the variant surface glycoprotein (VSG) of African trypanosomes play

271 The variant surface glycoprotein (VSG) of African trypanosomes, for

272 at consists of ten million copies of variant surface glycoprotein (VSG) that is expressed from a sing

273 y switches its major surface antigen variant surface glycoprotein (VSG) to evade mammalian host immun

274 ssing its major surface antigen, the Variant Surface Glycoprotein (VSG), in a monoallelic manner.

275 lies on RNA Pol I for expressing the variant surface glycoprotein (VSG), the key protein in antigenic

276 sely covered with highly immunogenic Variant Surface Glycoprotein (VSG).

277 hanging their antigenic coat made of variant surface glycoprotein (VSG).

278 densely packed surface monolayer of variant surface glycoprotein (VSG).

279 through antigenic variation of their Variant Surface Glycoprotein (VSG).

280 ching their dense protective coat of Variant Surface Glycoprotein (VSG).

281 tem is a dense coat that comprises a variant surface glycoprotein (VSG).

282 directed homologous recombination of Variant Surface Glycoproteins (VSG) genes, most of which reside

283 on due to antigenic variation of the Variant Surface Glycoproteins (VSG) that coat parasites while th

284 eriodically replacing a monolayer of variant surface glycoproteins (VSG) that covers its cell surface

285 the major antigenic determinant (the Variant Surface Glycoprotein, VSG gene) as well as TbORC1 bindin

286 arly, defective glycosylation of the variant surface glycoprotein (VSG221) as well as the lysosomal m

287 he sequential expression of distinct variant surface glycoproteins (VSGs) at extremely high density o

288 by periodically expressing different variant surface glycoproteins (VSGs).

289 RSV fusion (F) surface glycoprotein was modified and cloned into a bacu

290 Major surface glycoprotein was shown to greatly reduce beta-gl

291 IF5A in T. brucei in translation of variable surface glycoproteins were also uncovered.

292 Cluster of differentiation 8 (CD8) is a cell surface glycoprotein, which is expressed as 2 forms, alp

293 The neuraminidase (NA) surface glycoprotein, while diverse, has a conserved enz

294 leased from intracellular organelle and cell surface glycoproteins, while maintaining histopathology

295 Mesothelin is a cell-surface glycoprotein whose expression in normal human ti

296 adhesion molecule-1 (ICAM-1), an endothelial-surface glycoprotein whose expression is increased in pa

297 CD44 and CD24 are important cell surface glycoproteins whose relative expression levels a

298 Global analysis of surface glycoproteins will result in a better understand

299 Interaction of cell surface glycoproteins with endogenous lectins on the cel

300 aalpha2-6GalNAcalpha1-Ser/Thr, STn) on their surface glycoproteins, yet molecular mechanisms in terms